SunTrust Robinson Humphrey Initiates Coverage on La Jolla Pharmaceutical Company to Buy

SunTrust Robinson Humphrey Initiates Coverage on La Jolla Pharmaceutical Company(NASDAQ:LJPC). The shares have been rated Buy. The rating by SunTrust Robinson Humphrey was issued on Jun 22, 2016.

La Jolla Pharmaceutical Company (LJPC) shares turned negative on Mondays trading session with the shares closing down -1.33 points or -7.94% at a volume of 2,35,050. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $16.7. The peak price level was also seen at $16.7 while the days lowest was $15.39. Finally the shares closed at $15.42. The 52-week high of the shares is $44.9899 while the 52-week low is $12.68. According to the latest information available, the market cap of the company is $281 M.

La Jolla Pharmaceutical Company(LJPC) last announced its earnings results on May 6, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $234.00K. Analysts had an estimated revenue of $210.00K. Earnings per share were $-0.96. Analysts had estimated an EPS of $-0.74.

Several Insider Transactions has been reported to the SEC. On Sep 30, 2015, Lakhmir S Chawla (Chief Medical Officer) purchased 485 shares at $27.75 per share price.Also, On May 15, 2015, Saiid Zarrabian (director) purchased 307 shares at $19.50 per share price.On May 13, 2015, George F Tidmarsh (CEO) purchased 4,000 shares at $18.37 per share price, according to the Form-4 filing with the securities and exchange commission.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. Its four product candidates in development include LJPC-501 GCS-100 LJPC-1010 and LJPC-401. LJPC-501 is its formulation of angiotensin for the treatment of catecholamine-resistant hypotension (CRH). GCS-100 is its galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010 is its galectin-3 inhibitor. LJPC-401 is its formulation of hepcidin for the potential treatment of conditions characterized by iron overload such as hemochromatosis and beta thalassemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *